Caribou Biosciences Inc reports a Return on Equity (ROE) of -130.58%.

What is CRBU's dividend yield?

Caribou Biosciences Inc offers a dividend yield of 0.00%.

What is CRBU's Quality Score?

Our AI rates CRBU's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CRBU?

Our AI Timing Score for CRBU is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CRBU belong to?

Caribou Biosciences Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Caribou Biosciences Inc (CRBU) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

CRBU AI Analysis Summary

Our AI summary for CRBU: Caribou Biosciences Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -130.58%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CRBU

Caribou Biosciences Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 1.57

0.07 (4.67%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-130.6%

ROE

-89.4%

ROA

0.00%

Div Yield

CARIBOU BIOSCIENCES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.57 Price 0.07 (4.67%) Day Change	NEWS SCORE: 98

CRBU, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.57
PBV / Sector	1.46 / 44,022.72 GOOD
Earning Per Share	-1.41

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	2.94 M GREAT
Average 1W Daily Value	1.83 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1,189.14 / 98.24
NPM Average (%) / Sector	-1,004.47 / -1,697.63
NPM Change Average (%) / Sector	80.94 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-89.41 / 185,260.96
ROA Average (%) / Sector	-54.34 / 36,684.70
ROA Change Average (%) / Sector	43.41 / 422,221.66 GREAT
ROE (%) / Sector	-130.58 / 243,762.23
ROE Average (%) / Sector	-74.30 / 48,758.47
ROE Change Average (%) / Sector	52.50 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:01
Symbol	CRBU
Name	CARIBOU BIOSCIENCES INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	99.18 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	148.77 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2929 7th Street, Berkeley, CA, United States, 94710

Phone: 510 982 6030

Website: https://cariboubio.com

Employees: 97

Sector: Healthcare >> Biotechnology

Description: Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.